Immunic

Nov 04, 2021

•

Sep 30, 2021

Immunic Q3 2021 Earnings Report

Reported financial results for the third quarter ended September 30, 2021 and highlighted recent activity.

Key Takeaways

Immunic reported its third quarter 2021 financial results, highlighting the advancement of its clinical programs, including IMU-838 and IMU-935. The company's cash and cash equivalents totaled $110.4 million as of September 30, 2021, which is expected to fund operations into 2023.

Fully enrolled Phase 2 CALDOSE-1 trial of IMU-838 in moderate-to-severe ulcerative colitis.

Initiated Phase 2 CALLIPER trial in progressive multiple sclerosis, intended to run concurrently with and to complement the Company’s Phase 3 ENSURE Program in relapsing multiple sclerosis.

Cash and cash equivalents totaled $110.4 million as of September 30, 2021, expected to fund Immunic into 2023.

Expecting top-line data from the phase 2 CALDOSE-1 trial in the first half of 2022.